BioMS still positive as dirucotide fails to meet endpoint in Phase II MS trial
This article was originally published in Scrip
BioMS Medical's Phase II trial of its myelin basic protein stimulant, dirucotide, for the treatment of relapsing-remitting multiple sclerosis (RRMS) - developed with Lilly, has failed to meet its primary endpoint of annualised relapse rate or associated MRI measures. The news sent the company's shares down by 30% to close at Cdn$2.39 on January 30th on the Toronto Stock Exchange.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.